Analysts Are Bullish on These Healthcare Stocks: Nyxoah (NYXH), Moderna (MRNA)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nyxoah (NYXH – Research Report), Moderna (MRNA – Research Report) and Disc Medicine (IRON – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nyxoah (NYXH)
In a report released today, Adam Maeder from Piper Sandler maintained a Buy rating on Nyxoah, with a price target of $9.00. The company’s shares closed last Friday at $4.08.
According to TipRanks.com, Maeder is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nyxoah with a $10.26 average price target.
See the top stocks recommended by analysts >>
Moderna (MRNA)
In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Moderna, with a price target of $69.00. The company’s shares closed last Friday at $53.57.
According to TipRanks.com, Tenthoff is a 4-star analyst with an average return of
Moderna has an analyst consensus of Hold, with a price target consensus of $36.13.
Disc Medicine (IRON)
In a report released yesterday, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Disc Medicine, with a price target of $111.00. The company’s shares closed last Friday at $66.62, close to its 52-week high of $68.73.
According to TipRanks.com, Willey is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Disc Medicine with a $104.55 average price target, representing a 54.9% upside. In a report issued on February 17, H.C. Wainwright also maintained a Buy rating on the stock with a $118.00 price target.
